| Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA Z Zou, B Huang, X Wu, H Zhang, J Qi, J Bradner, S Nair, LF Chen Oncogene 33 (18), 2395-2404, 2014 | 286 | 2014 |
| An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling Z Karoulia, Y Wu, TA Ahmed, Q Xin, J Bollard, C Krepler, X Wu, C Zhang, ... Cancer cell 30 (3), 485-498, 2016 | 175 | 2016 |
| SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors TA Ahmed, C Adamopoulos, Z Karoulia, X Wu, R Sachidanandam, ... Cell reports 26 (1), 65-78. e5, 2019 | 168 | 2019 |
| Brd4 modulates the innate immune response through Mnk2–eIF4E pathway-dependent translational control of IκBα Y Bao, X Wu, J Chen, X Hu, F Zeng, J Cheng, H Jin, X Lin, LF Chen Proceedings of the National Academy of Sciences 114 (20), E3993-E4001, 2017 | 67 | 2017 |
| Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF … X Wu, J Qi, JE Bradner, G Xiao, LF Chen Journal of Biological Chemistry 288 (50), 36094-36105, 2013 | 44 | 2013 |
| Distinct spatiotemporal expression of ISM1 during mouse and chick development L Osório, X Wu, Z Zhou Cell Cycle 13 (10), 1571-1582, 2014 | 42 | 2014 |
| Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer YH Nicole Tsang, XW Wu, JS Lim, C Wee Ong, M Salto-Tellez, K Ito, Y Ito, ... Oncogene 32 (12), 1488-1496, 2013 | 42 | 2013 |
| AKT degradation selectively inhibits the growth of PI3K/PTEN pathway–mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B J Xu, X Yu, TC Martin, A Bansal, K Cheung, A Lubin, E Stratikopoulos, ... Cancer discovery 11 (12), 3064-3089, 2021 | 39 | 2021 |
| Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders X Wu, X Yang, Y Xiong, R Li, T Ito, TA Ahmed, Z Karoulia, C Adamopoulos, ... Nature cancer 2 (4), 429-443, 2021 | 39 | 2021 |
| Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling C Adamopoulos, TA Ahmed, MR Tucker, PMU Ung, M Xiao, Z Karoulia, ... Cancer discovery 11 (7), 1716-1735, 2021 | 35 | 2021 |
| ISM1 regulates NODAL signaling and asymmetric organ morphogenesis during development L Osório, X Wu, L Wang, Z Jiang, C Neideck, G Sheng, Z Zhou Journal of Cell Biology 218 (7), 2388-2402, 2019 | 25 | 2019 |
| Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis … EE Stratikopoulos, N Kiess, M Szabolcs, S Pegno, C Kakit, X Wu, ... Oncogene 38 (1), 47-59, 2019 | 23 | 2019 |
| Global view of the RAF-MEK-ERK module and its immediate downstream effectors CC Santini, J Longden, EM Schoof, CD Simpson, GR Jeschke, P Creixell, ... Scientific Reports 9 (1), 10865, 2019 | 14 | 2019 |
| A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma RW Zhou, J Xu, TC Martin, AL Zachem, J He, S Ozturk, D Demircioglu, ... Nature Communications 13 (1), 6041, 2022 | 13 | 2022 |
| Compositions and methods for treating CDK4/6-mediated cancer J Jin, X Yang, J Liu, Y Xiong, P Poulikakos, Z Karoulia, X Wu, T Ahmed US Patent 11,541,051, 2023 | 8 | 2023 |
| Compositions and methods for treating CDK4/6-mediated cancer J Jin, X Yang, J Liu, Y Xiong, P Poulikakos, Z KAROULIA, X Wu, ... | 7 | 2018 |
| Compositions and methods for treating cdk4/6-mediated cancer J Jin, X Yang, J Liu, Y Xiong, P Poulikakos, Z Karoulia, X Wu, T Ahmed US Patent App. 17/453,619, 2022 | 5 | 2022 |
| Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders P Poulikakos, X Wu, X Yang, Y Xiong, T Ito, T Ahmed, Z Karoulia, ... European Journal of Cancer 138, S5, 2020 | 1 | 2020 |
| Abstract LB-119: SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors C Adamopoulos, TA Ahmed, Z Karoulia, X Wu, R Sachidanandam, ... Cancer Research 79 (13_Supplement), LB-119-LB-119, 2019 | 1 | 2019 |
| Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6 X Wu, X Yang, Y Xiong, R Li, T Ito, T Ahmed, Z Karoulia, C Adamopoulos, ... Cancer Research 81 (13_Supplement), 41-41, 2021 | | 2021 |
Poulikos I. PoulikakosIcahn School of Medicine at Mount SinaiVerified email at mssm.edu
